Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Sign Out
Sign In | Create Account
  • Rare Bleeding Disorders Home
    • Products
      Our Treatments How to Order Trial Prescriptions Recombinant Manufacturing
    • Professional Resources
      Product Resources Library Contact Your Representative
    • Disease Education
      Clinical Education Library Congenital Hemophilia with Inhibitors Acquired Hemophilia Glanzmann's Thrombasthenia Interactive Joint Bleed Model
    • Treatment Guidelines
      MASAC Guidelines WFH Guidelines
    • Additional Resources
      Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Resources
    • Access & Affordability
      Prescription Savings & Insurance Support
  • Sign In
    Create Account
    • Account Settings
    • Sign Out
    Other Therapy Areas
    Medical Information
    Non-US Health Care Professionals
NovoSeven® RT (coagulation Factor VIIa, recombinant) logo
Important Safety Information | Patient Site
Prescribing Information
    • Why NovoSeven® RT?
    • Pharmacology
    • Congenital Hemophilia A & B with Inhibitors
    • Acquired Hemophilia
    • Congenital Factor VII Deficiency
    • Glanzmann's Thrombasthenia
    • Hospital Overview
    • Clinical Pathway for Emergent Bleeds
    • Clinical Pathway for Acquired Hemophilia
    • Hospital Pharmacies
    • Dosing Calculator
    • Quick Reference
    • Administration
  • Cost & Coverage
    • Patient Education
    • Education for You
    • How to Order
NovoSeven® RT (coagulation Factor VIIa, recombinant) logo

Indicated for treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital factor VII (FVII) deficiency, Glanzmann’s thrombasthenia with refractoriness to platelet transfusions and in adults with acquired hemophilia.

Prescribing Information
Important Safety Information | Patient Site

Success speaks for itself

“I’ll never forget my first patient. When his life was in danger, I knew where to turn for a fast treatment.”1

Why NovoSeven® RT

Experience you can count on

With 30+ years of experience, NovoSeven® RT continues to provide bleed control professionals and patients can trust.1 It helps patients with the broadest range of bleeding disordersa as compared to FEIBA® and Obizur®.2-4

Why NovoSeven® RT

Actor portrayal

Experience you can count on

With 30+ years of experience, NovoSeven® RT continues to provide bleed control professionals and patients can trust.1 It helps patients with the broadest range of bleeding disordersa as compared to FEIBA® and Obizur®.2-4

Why NovoSeven® RT

Success speaks for itself

“I’ll never forget my first patient. When his life was in danger, I knew where to turn for a fast treatment.”1

Why NovoSeven® RT

Actor portrayal

Bleeds happen. Treat fast. After 30+ years of research and clinical experience across more indicationsa than any other agent in its category, NovoSeven® RT continues to be a reliable choice today.2-6

aIndicated for bleed control and surgery in 4 bleeding disorders: CHAwI or CHBwI, AH, CFVIId, and GT.2

See efficacy and safety profile data for patients with:

Congenital Hemophilia A or B With Inhibitors

Acquired Hemophilia
 

Congenital Factor VII Deficiency
 

Glanzmann’s Thrombasthenia
 


Dosing tools and recommendations

NovoSeven® RT vials
Use this convenient dosing calculator

With this dosing calculator, you can quickly determine the recommended NovoSeven® RT dose for your patient, plus the number of vials required.*

Calculate a dose

*As a reminder, for US health care professionals only.

Get quick dosing
recommendations

The quick reference dosing page provides recommended doses for all indications.

See recommendations
NovoSeven® RT vial
Steps for administering NovoSeven® RT

MixPro® makes preparing a dose of NovoSeven® RT fast for your patients.

Review the steps
Administering NovoSeven® RT
Person extracting the NovoSeven® RT medication from vial
The #1 prescribed rFVIIa in hospitals.5

NovoSeven® RT is approved for bleed control and perioperative management in a wide range of indications.1 NovoSeven® RT is the only rFVIIa that has clinical study experience with Hemlibra® for patients with CHAwI.6 Explore information and clinical pathways for treating bleeding episodes and for perioperative management.

Explore hospital use
The #1 prescribed rFVIIa in hospitals.5

NovoSeven® RT is approved for bleed control and perioperative management in a wide range of indications.1 NovoSeven® RT is the only rFVIIa that has clinical study experience with Hemlibra® for patients with CHAwI.6 Explore information and clinical pathways for treating bleeding episodes and for perioperative management.

Explore hospital use
Illustration of patient at hospital with a doctor and nurse


Other tools and resources to help you and your patients

How NovoSeven® RT works

Review the mechanism of action (MOA) of NovoSeven® RT for congenital hemophilia with inhibitors.

Find MOA info
Ordering NovoSeven® RT
How to order

Learn how you can order NovoSeven® RT for your patients with rare bleeding disorders.

See how to order
Education for you

Browse educational materials for health care professionals who treat patients with bleeding disorders.

Find professional resources
Support for patients

See how we may be able to help your patients with insurance coverage or financial assistance.

Find coverage options
Education for you

Browse educational materials for health care professionals who treat patients with bleeding disorders.

Find professional resources
Support for patients

See how we may be able to help your patients with insurance coverage or financial assistance.

Find coverage options

Questions about how NovoSeven® RT can help your patients?

Selected Important Safety Information for NovoSeven® RT

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
  • Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events

Indications and Usage

NovoSeven® RT (coagulation Factor VIIa, recombinant) is a coagulation factor indicated for:

  • Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
  • Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia

Important Safety Information

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
  • Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events
  • Hypersensitivity reactions, including anaphylaxis, can occur with NovoSeven® RT. Patients with a known hypersensitivity to mouse, hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions. Discontinue infusion and administer appropriate treatment when hypersensitivity reactions occur
  • Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed
  • Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis

Adverse Reactions

  • The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NovoSeven® RT in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia

Drug Interactions

  • Thrombosis may occur if NovoSeven® RT is administered concomitantly with Coagulation Factor XIII

Please click here for NovoSeven® RT Prescribing Information, including Boxed Warning.

References
  1. Data on file. Novo Nordisk Inc; Plainsboro, NJ.
  2. NovoSeven RT [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2020.
  3. FEIBA [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; 2020.
  4. Obizur [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; 2021.
  5. Data on file as of 2021. Novo Nordisk Inc; Plainsboro, NJ.
  6. Levy GG, Asikanius E, Kuebler P, et al. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: experience from the HAVEN clinical program. J Thromb Haemost. 2019;17(9):1470-1477.
Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
  • Rare Bleeding Disorders Home
  • Product Information
    Products
    • Our Treatments
      How to Order
      Trial Prescriptions
      Recombinant Manufacturing
    Professional Resources
    • Product Resources Library
      Contact Your Representative
  • Professional Education
    Disease Education
    • Clinical Education Library
      Congenital Hemophilia with Inhibitors
      Acquired Hemophilia
      Glanzmann's Thrombasthenia
      Interactive Joint Bleed Model
    Treatment Guidelines
    • MASAC Guidelines
      WFH Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Resources
    Access & Affordability
    • Prescription Savings & Insurance Support

NovoSeven®, and MixPro® are registered trademarks and novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.

Legal Notice | Privacy Policy | Cookie Policy | Contact Us |
novonordisk-us.com    
© 2022 Novo Nordisk All rights reserved.  US21NSVN00130 July 2022

Quick links

Trial prescription programs

Patient access and affordability options

MASAC treatment guidelines

Patient educational materials